These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 8652235

  • 1. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.
    Seymour AM, de Campos E, Thatcher N, De Greve J, Cunningham D, Howell A, Tueni E, Bron DG, Steward WP, Berdel WE.
    Eur J Cancer; 1995 Dec; 31A(13-14):2157-63. PubMed ID: 8652235
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
    Nohynek GJ, Plard JP, Wells MY, Zerial A, Roquet F.
    Cancer Chemother Pharmacol; 1997 Dec; 39(3):259-66. PubMed ID: 8996530
    [Abstract] [Full Text] [Related]

  • 3. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.
    Gisselbrecht C, Haioun C, Lepage E, Bastion Y, Tilly H, Bosly A, Dupriez B, Marit G, Herbrecht R, Deconinck E, Marolleau JP, Yver A, Dabouz-Harrouche F, Coiffier B, Reyes F.
    Leuk Lymphoma; 1997 Apr; 25(3-4):289-300. PubMed ID: 9168439
    [Abstract] [Full Text] [Related]

  • 4. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
    Narabayashi M, Takeyama K, Fukutomi T, Tokuda Y, Tajima T, Okumura A, Chou T, Sano M, Makino H, Igarashi T, Sasaki Y, Imoto S, Ogura M, Morishima Y, Murai H, Okamoto S, Ikeda T, Kasai M, Yokozawa T, Tobinai K.
    Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556
    [Abstract] [Full Text] [Related]

  • 5. Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.
    Keating GM.
    Drugs; 2011 Apr 16; 71(6):679-707. PubMed ID: 21504247
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A randomized, crossover comparison of standard-dose versus low-dose lenograstim in the prophylaxis of post-chemotherapy neutropenia.
    Juan O, Campos JM, Carañana V, Sanchez JJ, Casañ R, Alberola V.
    Support Care Cancer; 2001 Jun 16; 9(4):241-6. PubMed ID: 11430419
    [Abstract] [Full Text] [Related]

  • 11. Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison.
    Toner GC, Shapiro JD, Laidlaw CR, Rischin D, Millward MJ, Wolf M, Januszewicz H, Mitchell SV, Curran AC, Matthews JP, Bishop JF.
    J Clin Oncol; 1998 Dec 16; 16(12):3874-9. PubMed ID: 9850033
    [Abstract] [Full Text] [Related]

  • 12. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group.
    Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H.
    N Engl J Med; 1995 Jun 22; 332(25):1678-83. PubMed ID: 7539109
    [Abstract] [Full Text] [Related]

  • 13. A European phase II study of recombinant human granulocyte colony-stimulating factor (lenograstim) in the treatment of severe chronic neutropenia in children. Lenograstim Study Group.
    Donadieu J, Boutard P, Bernatowska E, Tchernia G, Couillaud G, Philippe N, Le Gall E.
    Eur J Pediatr; 1997 Sep 22; 156(9):693-700. PubMed ID: 9296532
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical trial of low-dose rHuG-CSF in neutropenic cancer patients following anti-cancer chemotherapy.
    Chang MC, Lai GM, Tsan KW, Wang RS, Wu JH.
    J Formos Med Assoc; 1996 Nov 22; 95(11):845-50. PubMed ID: 8990772
    [Abstract] [Full Text] [Related]

  • 19. Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy.
    Yakushijin Y, Shikata H, Takaoka I, Horikawa T, Takeuchi K, Yamanouchi J, Azuma T, Narumi H, Hato T, Yasukawa M.
    Int J Clin Oncol; 2011 Apr 22; 16(2):118-24. PubMed ID: 20924633
    [Abstract] [Full Text] [Related]

  • 20. Comparison of filgrastim and lenograstim in pediatric solid tumors.
    Sarı N, Dalva K, Ilhan IE.
    Pediatr Hematol Oncol; 2013 Oct 22; 30(7):655-61. PubMed ID: 24050764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.